Opinion
Video
Managing Disease Progression in MS: Changing Treatments and Clinician Advice
Author(s):
Key Takeaways
- Disease progression on high-efficacy therapy necessitates strategic treatment modification, considering both within-class switches and different mechanisms of action based on patient response.
- Switching within the same class may be appropriate for partial response or tolerability issues, while a different mechanism is advised for complete lack of efficacy.
Panelists discuss how in multiple sclerosis (MS) treatment, clinicians must strategically evaluate disease progression, considering within-class or mechanism-of-action switches. Comprehensive monitoring, personalized approaches, and proactive management are crucial for optimizing patient outcomes and minimizing long-term neurological disability.
Video content above is prompted by the following:
- In cases where a patient continues to show disease progression on a high-efficacy therapy, what is your approach to changing treatment? When would you recommend switching within class and when to a different mechanism of action?
- In closing, what advice would you like to share with clinicians who are taking care of patients with MS?
Related Videos
Related Content
